These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 32377737)

  • 1. 7ND protein exerts inhibitory effects on both osteoclast differentiation in vitro and lipopolysaccharide‑induced bone erosion in vivo.
    Long W; Quan J; Liu Y; Li J; Gong Q; Jiang H
    Mol Med Rep; 2020 Jul; 22(1):97-104. PubMed ID: 32377737
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theaflavin-3,3'-digallate represses osteoclastogenesis and prevents wear debris-induced osteolysis via suppression of ERK pathway.
    Hu X; Ping Z; Gan M; Tao Y; Wang L; Shi J; Wu X; Zhang W; Yang H; Xu Y; Wang Z; Geng D
    Acta Biomater; 2017 Jan; 48():479-488. PubMed ID: 27838465
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant monocyte chemoattractant protein-1 protein (7ND) inhibits osteoclast differentiation and reduces oral squamous carcinoma cell bone invasion.
    Luo S; Zhou C; Zhang J; Chen M; Li H; Zheng S; Quan J
    Oncol Lett; 2018 May; 15(5):7760-7768. PubMed ID: 29725470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Licorice isoliquiritigenin-encapsulated mesoporous silica nanoparticles for osteoclast inhibition and bone loss prevention.
    Sun X; Zhang J; Wang Z; Liu B; Zhu S; Zhu L; Peng B
    Theranostics; 2019; 9(18):5183-5199. PubMed ID: 31410209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alexidine Dihydrochloride Attenuates Osteoclast Formation and Bone Resorption and Protects Against LPS-Induced Osteolysis.
    Zhu X; Gao J; Ng PY; Qin A; Steer JH; Pavlos NJ; Zheng MH; Dong Y; Cheng TS
    J Bone Miner Res; 2016 Mar; 31(3):560-72. PubMed ID: 26363136
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paeoniflorin Inhibits Receptor Activator for Nuclear Factor κB (RANK) Ligand-Induced Osteoclast Differentiation In Vitro and Particle-Induced Osteolysis In Vivo.
    Li Z; Li D; Chen X
    Med Sci Monit; 2018 Feb; 24():1044-1053. PubMed ID: 29459582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diallyl disulfide alleviates inflammatory osteolysis by suppressing osteoclastogenesis
    Yang J; Tang R; Yi J; Chen Y; Li X; Yu T; Fei J
    FASEB J; 2019 Jun; 33(6):7261-7273. PubMed ID: 30857415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Arctigenin inhibits RANKL-induced osteoclastogenesis and hydroxyapatite resorption in vitro and prevents titanium particle-induced bone loss in vivo.
    Wei G; Liang T; Wei C; Nong X; Lu Q; Zhao J
    J Cell Biochem; 2019 Apr; 120(4):5367-5376. PubMed ID: 30317692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bisphosphonates inhibit osteosarcoma-mediated osteolysis via attenuation of tumor expression of MCP-1 and RANKL.
    Ohba T; Cole HA; Cates JM; Slosky DA; Haro H; Ando T; Schwartz HS; Schoenecker JG
    J Bone Miner Res; 2014 Jun; 29(6):1431-45. PubMed ID: 24443409
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hypericin suppresses osteoclast formation and wear particle-induced osteolysis via modulating ERK signalling pathway.
    Ouyang Z; Zhai Z; Li H; Liu X; Qu X; Li X; Fan Q; Tang T; Qin A; Dai K
    Biochem Pharmacol; 2014 Aug; 90(3):276-87. PubMed ID: 24950468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dehydrocostus lactone attenuates osteoclastogenesis and osteoclast-induced bone loss by modulating NF-κB signalling pathway.
    Hu B; Wu F; Shi Z; He B; Zhao X; Wu H; Yan S
    J Cell Mol Med; 2019 Aug; 23(8):5762-5770. PubMed ID: 31225720
    [TBL] [Abstract][Full Text] [Related]  

  • 12. LY411575, a potent γ-secretase inhibitor, suppresses osteoclastogenesis in vitro and LPS-induced calvarial osteolysis in vivo.
    Chen X; Chen X; Zhou Z; Qin A; Wang Y; Fan B; Xu W; Zhang S
    J Cell Physiol; 2019 Nov; 234(11):20944-20956. PubMed ID: 31020651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monocrotaline Suppresses RANKL-Induced Osteoclastogenesis In Vitro and Prevents LPS-Induced Bone Loss In Vivo.
    Wei CM; Su YJ; Qin X; Ding JX; Liu Q; Song FM; Zong SH; Xu J; Zhou B; Zhao JM
    Cell Physiol Biochem; 2018; 48(2):644-656. PubMed ID: 30025412
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sinomenine down-regulates TLR4/TRAF6 expression and attenuates lipopolysaccharide-induced osteoclastogenesis and osteolysis.
    He L; Duan H; Li X; Wang S; Zhang Y; Lei L; Xu J; Liu S; Li X
    Eur J Pharmacol; 2016 May; 779():66-79. PubMed ID: 26965104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nirogacestat suppresses RANKL-Induced osteoclast formation in vitro and attenuates LPS-Induced bone resorption in vivo.
    Chen X; Chen X; Zhou Z; Mao Y; Wang Y; Ma Z; Xu W; Qin A; Zhang S
    Exp Cell Res; 2019 Sep; 382(1):111470. PubMed ID: 31211955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of protein kinase C-δ protects against LPS-induced osteolysis owing to an intrinsic defect in osteoclastic bone resorption.
    Khor EC; Abel T; Tickner J; Chim SM; Wang C; Cheng T; Ng B; Ng PY; Teguh DA; Kenny J; Yang X; Chen H; Nakayama KI; Nakayama K; Pavlos N; Zheng MH; Xu J
    PLoS One; 2013; 8(8):e70815. PubMed ID: 23951014
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chlorogenic acid inhibits osteoclast differentiation and bone resorption by down-regulation of receptor activator of nuclear factor kappa-B ligand-induced nuclear factor of activated T cells c1 expression.
    Kwak SC; Lee C; Kim JY; Oh HM; So HS; Lee MS; Rho MC; Oh J
    Biol Pharm Bull; 2013; 36(11):1779-86. PubMed ID: 23985829
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desoxyrhapontigenin inhibits RANKL‑induced osteoclast formation and prevents inflammation‑mediated bone loss.
    Tran PT; Park DH; Kim O; Kwon SH; Min BS; Lee JH
    Int J Mol Med; 2018 Jul; 42(1):569-578. PubMed ID: 29693149
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Daphnetin attenuates LPS-induced osteolysis and RANKL mediated osteoclastogenesis through suppression of ERK and NFATc1 pathways.
    Wu Z; Wu H; Li C; Fu F; Ding J; Shao S; Li K; Yu X; Su Y; Liang J; Lin X; Yuan G; Zhou J; Song F; Zhao J; Xu J; Liu Q; Xu F
    J Cell Physiol; 2019 Aug; 234(10):17812-17823. PubMed ID: 30815894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutant CCL2 protein coating mitigates wear particle-induced bone loss in a murine continuous polyethylene infusion model.
    Nabeshima A; Pajarinen J; Lin TH; Jiang X; Gibon E; Córdova LA; Loi F; Lu L; Jämsen E; Egashira K; Yang F; Yao Z; Goodman SB
    Biomaterials; 2017 Feb; 117():1-9. PubMed ID: 27918885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.